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BACKGROUND: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC),
clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in
epithelial ovarian cancer in a large population-based study.
METHODS: Tumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue
Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time,
age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER),
progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised
Cochran–Mantel–Haenszel tests.
RESULTS: Downregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients;
p value= 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65–0.94,
p value= 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in
HGSOC and with lower CD8 counts in CCOC (p value < 0.0001). Heterogeneous expression of PTEN was more prevalent in advanced
HGSOC (p value= 0.019) and associated with higher CD8 counts (p value= 0.0016).
CONCLUSIONS: PTEN loss is a frequent driver in ovarian carcinoma associating distinctly with expression of hormonal receptors
and CD8+ TIL counts in HGSOC and CCOC histotypes.
British Journal of Cancer (2020) 123:793–802; https://doi.org/10.1038/s41416-020-0900-0
BACKGROUND
Ovarian cancer is the fifth leading cause of female cancer mortality
and advances in the last decades have not translated into
increased survival.1 High-grade serous ovarian cancer (HGSOC) is
the most common histotype of ovarian cancer and is characterised
by extreme genomic instability and chromosomal rearrange-
ments. HGSOC has ubiquitous TP53 mutation, common mutations
of BRCA1 and BRCA2 and amplification of CCNE1, MYC and PIK3CA
(reviewed in ref. 2). Other common ovarian cancer histotypes are
endometrioid (ENOC), clear cell (CCOC), mucinous (MOC) and low-
grade serous (LGSOC) which have specific drivers and different
cells of origin.1
Phosphatase and tensin homologue (PTEN) is a potent tumour
suppressor classically known for its role in the inhibition of the
phosphoinositide-3 kinase (PI3K) pathway. PTEN regulates cell
proliferation, migration, survival, genomic stability and metabo-
lism by phosphatase-dependent and phosphatase-independent
activities.3 Loss of PTEN was associated with immunoresistance
and worse response to programmed cell death protein 1 (PD-1)
inhibitors in preclinical murine models of melanoma, by decreas-
ing T cell trafficking into the tumours and T cell-mediated cell
death in the tumour. Treatment with selective PI3Kbeta inhibitor
improved the efficacy of both anti-PD-1 and anti-cytotoxic
T-lymphocyte-associated protein 4 (anti-CTLA-4) antibodies in
mouse models.3,4 Even subtle changes of PTEN expression may
influence tumour initiation and progression as it is strongly
regulated by critical molecular networks in which activation of
hormonal receptors seems to have an important role.5
In ovarian cancer, mutation of PTEN has been a reported
driver in endometrioid and clear cell subtypes.6–10 Homozygous
loss of PTEN is found in 6% of HGSOC11 and loss-of-function
mutations of Pten allow for accelerated tumour growth in mouse
and in vitro models of HGSOC and ENOC.12–14 We previously
demonstrated that PTEN loss is prevalent in HGSOC using
bioinformatics and image analysis methods that corrected for
cellularity in gene expression signatures from The Cancer
Genome Atlas.15 PTEN and AR gene expression were significantly
correlated and had positive survival effects. However, this and
previous studies are limited by modest sample sizes and
potential effects of different assay methods. Large-scale analysis
of PTEN protein expression has not been carried out across the
ovarian histotypes.
Therefore, we hypothesised that accurate estimates of PTEN
loss across a large population would reveal histotype-specific
associations with clinical and pathological factors using clinically
relevant immunohistochemical (IHC) assays for PTEN, CD8 and the
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hormone receptors oestrogen receptor (ER), progesterone recep-
tor (PR) and androgen receptor (AR).16,17 The prevalence of PTEN
loss and the above associations will inform the likelihood of loss of
PTEN being a driver.
METHODS
Study design and participants
A total of 5400 women with ovarian cancer from 20 participating
sites in the Ovarian Tumour Tissue Analysis (OTTA) Consortium
with an average length of follow-up of 5.5 years were included in
this study. We requested and received institutional review board/
ethics board approval from the institutions participating in the
OTTA Consortium. Patients were not provided compensation for
their participation in the study at any site. Average length of
follow-up per histotype were approximately 4.4 years for HGSOC,
7.6 for ENOC, 7.2 for CCOC, 6.6 for MOC and 5.8 for LGSOC
(Table 1; Supplementary Table S1). One-third of the patients had
delayed entry into the study, and for these cases, the mean
enrolment time was 1.4 years post-diagnosis.
Demographic, clinical and pathological variables, including
age at diagnosis, tumour stage and grade, presence or absence
of post-operative residual tumour and scores for expression
of PTEN, CD8, PR, AR and ER expression were used for the
association analysis. Table 1 shows the absolute and relative
number of histotype-specific participants with the variables
mentioned above. Samples were obtained from pelvic disease
and all the histological diagnosis were reviewed by experienced
pathologists. Supplementary Table 1 provides information on
variable-specific times of follow-up in person-years. Supplemen-
tary Fig. 1 summarises the analysis of missing data. Site
dependency in missing data pattern was mostly due to different
entry times into OTTA for different participant sites. Age at
diagnosis was rarely missing (0.5%). The average age at diagnosis
was slightly >60 years for HGSOC and around 55 years for other
histotypes. Status at last follow-up, time of last follow-up and
time of enrolment were mostly present (missed in 2.25, 1.5 and
0.65% of the cases, respectively). In all, 41% of the patients were
still alive at the time of last follow-up. Causes of death were
disease or treatment in 65.5% of the patients and unknown in
27.8% of the patients.
IHC analysis and scoring
IHC for PTEN was carried out in Cambridge (UK) using tissue
microarrays (TMAs) obtained from formalin-fixed, paraffin-
embedded tissues and primary antibody for PTEN (Cell Signaling,
Danvers, MA, USA; PTEN—Clone 138G6) as previously described.15,18
The PTEN expression assay was previously validated using external
positive and negative controls including mouse tissues from a
conditional PTEN knockout model.18 PTEN scoring used normal
stroma as an internal control. Heat-induced antigen retrieval was
carried out in 10mmol l−1 citric acid (pH 6.0) in a pressure cooker at
120 °C for 10min. Sections were incubated overnight with PTEN
antibody diluted 1:100 in 5% goat serum, followed by a 1-h
incubation with anti-rabbit biotinylated secondary antibody and
peroxidase-conjugated avidin–biotin complexes (Elite ABC; Vector
Laboratories, Burlingame, CA, USA). Formed immunocomplexes
were visualised using diaminobenzidine (DAB; DAKO, Glostrup,
Denmark, EU), and slides were counterstained with haematoxylin.
Sections were rinsed in phosphate-buffered saline between each
step. IHC staining for AR was performed in Vancouver using the
Ventana Discovery Ultra machine (Ventana Medical Systems Inc.,
Tuscon, AZ, USA). Sections underwent 36min of Cell Conditioning 1
(Ventana Medical Systems) before incubation with AR antibody
(Santa Cruz sc-815) titrated at 1:50 for 60min at 37 °C. Antibody
expression was detected using the DAB Map Detection Kit (Ventana
Medical Systems) with the Universal Secondary Antibody (Ventana
Medical Systems). Updated data for CD8, ER and PR staining was
obtained from the OTTA Consortium.16,17
IHC samples were stored at room temperature (RT) for at least
48 h before image analysis. For IHC, an Ariol scanning system
(Leica, Wetzlar, Germany) was used to obtain the digital images.
Scoring was performed according to intensity (using stromal cells
as internal positive controls) and the percentage of stained cells.
Reproducibility was scored by two independent observers (A.P.,
F.C.M.) from a randomly assigned data set of 678 cases taken from
all TMAs. Cytoplasmic and nuclear staining in the tumour cells was
assessed separately. Cytoplasmic staining was scored as negative
(no staining in any tumour cell with internal stromal control
present), weak positive (all tumour cells with weaker staining
compared to stromal cells), positive (all tumour and stromal cells
equally stained) or heterogeneous (combination of positive and
negative/weak staining) staining. Nuclear staining was scored
based on the percentage of cells with positive nuclei for PTEN (0%;
0–10%; 10–50%; >50%).
For AR IHC, positive was defined as nuclear expression in >1% of
tumour cells.
Statistical analysis
We used the generalised Cochran–Mantel–Haenszel (gCMH) tests
to perform nominal and/or ordinal associations between cyto-
plasmic PTEN expression and relevant clinical, pathological and
demographic variables within each histotype. For ordinal associa-
tions, only negative, weak and positive levels of PTEN expression
were included.
The gCMH test is equivalent to the Pearson’s Chi-Square test for
nominal–nominal associations, to the extended Cochran–Armitage
test for nominal–ordinal associations and to the linear-by-linear
association test for ordinal–ordinal associations.19 We assigned
equidistant scores for ordinal levels. We used Holm’s multiplicity
correction, valid under arbitrary assumptions, to achieve a global
type I error of 5% per analysis and histotype. All p values presented
in the manuscript are adjusted for multiplicity correction.
Significant associations were visualised using mosaic plots,
which represent the different contingency table cells, in which the
area of the tiles is proportional to the observed frequencies. Each
tile is coloured depending on its contribution to the Pearson’s
Chi-square statistics. For example, blue and red tiles correspond,
respectively, to the cells showing frequencies smaller and greater
than expected under the independence assumption. Further tests
were performed to describe associations that were significant or
clinically relevant.
In order to determine disease-specific survival associations with
cytoplasmic PTEN expression, we used clinical data censored at 10
years from diagnosis and fitted Cox proportional hazard models
stratified by site. With the exception of the cases with LGSOC,
which had a small observed sample size, we controlled for age
(and age squared), stage (four levels: I/II/III/IV), and post-operative
residual tumour (2 levels: Yes/No). Survival times were left-
truncated to obtain unbiased parameter estimates with delayed
entries (refer to Section 3.5 of ref. 20 for detail), as well as right-
censored for patients still alive after 10 years of follow-up or
deceased owing to other causes. Deaths due to unknown causes
were considered as disease related. We analysed the deviance and
Schoenfeld residuals as model checks and performed sensitivity
analyses by running the same analyses on data with imputed
missing predictors21 and by controlling for the biomarkers CD8,
ER, PR and AR independently or jointly (refer to Supplementary
Material for detail). All IHC markers investigated were pre-specified
before the analysis, and all statistical analyses were corrected for
multiple testing. In the survival analyses, we used a multiplicity
correction, which takes the dependence between the PTEN
parameters of interest into account and allows for a global 5%
type I error rate per histotype.22
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Table 1. Summary of the demographics of the study cohort stratified by cancer histotype.
Cancer type Total
HGSOC ENOC CCOC MOC LGSOC
Age at diagnosis
Mean 60.4 55.4 56.6 55.2 53.9 58.5
SD 11.2 12.4 11.7 15.2 13.1 12.1
Years followed
Mean 4.4 7.6 7.2 6.6 5.8 5.5
SD 3.6 4.8 5.6 5.3 4.3 4.5
Delayed entry
Mean 0.4 0.6 0.5 0.6 0.6 0.5
Yes (%) 31.1 33.9 31.8 36.3 30.7 32
Mean if yes 1.2 1.9 1.7 1.8 1.9 1.4
SD if yes 1.7 2.3 2.5 2.2 1.9 2
Number of cases (% per cancer subtype)
Total 3244 (100) 840 (100) 693 (100) 405 (100) 218 (100) 5400 (100)
Status at follow-up
Data available 3185 (100) 810 (100) 673 (100) 396 (100) 213 (100) 5277 (100)
Alive 908 (29) 550 (68) 369 (55) 238 (60) 112 (53) 2177 (41)
Dead (disease) 1619 (51) 107 (13) 140 (21) 69 (17) 71 (33) 2006 (38)
Dead (treatment) 17 (1) 4 (0) 2 (0) 0 (0) 2 (1) 25 (0)
Dead (other) 113 (4) 40 (5) 28 (4) 22 (6) 3 (1) 206 (4)
Dead (unknown) 528 (17) 109 (13) 134 (20) 67 (17) 25 (12) 863 (16)
FIGO stage
Data available 2882 (100) 667 (100) 591 (100) 324 (100) 179 (100) 4643 (100)
Stage I 236 (8) 342 (51) 295 (50) 217 (67) 45 (25) 1135 (24)
Stage II 284 (10) 189 (28) 154 (26) 36 (11) 18 (10) 681 (15)
Stage III 1994 (69) 122 (18) 130 (22) 60 (19) 104 (58) 2410 (52)
Stage IV 368 (13) 14 (2) 12 (2) 11 (3) 12 (7) 417 (9)
Differentiation
Data available 2952 (100) 792 (100) 452 (100) 381 (100) 209 (100) 4786 (100)
Well 1 (0) 328 (41) 16 (4) 151 (40) 176 (84) 672 (14)
Moderate 376 (13) 251 (32) 57 (13) 173 (45) 3 (1) 860 (18)
Poor/none 2575 (87) 213 (27) 379 (84) 57 (15) 30 (14) 3254 (68)
Residual tumour
Data available 2118 (100) 462 (100) 444 (100) 237 (100) 133 (100) 3394 (100)
Yes 1176 (56) 57 (12) 91 (20) 57 (24) 62 (47) 1443 (43)
No 942 (44) 405 (88) 353 (80) 180 (76) 71 (53) 1951 (57)
Cytoplasmic PTEN
Data available 2915 (100) 775 (100) 644 (100) 360 (100) 185 (100) 4879 (100)
Negative 550 (19) 273 (35) 208 (32) 69 (19) 21 (11) 1121 (23)
Weak 1455 (50) 312 (40) 312 (48) 147 (41) 90 (49) 2316 (47)
Positive 733 (25) 157 (20) 107 (17) 124 (34) 64 (35) 1185 (24)
Heterogeneous 177 (6) 33 (4) 17 (3) 20 (6) 10 (5) 257 (5)
Nuclear PTEN
Data available 2910 (100) 774 (100) 643 (100) 359 (100) 185 (100) 4871 (100)
0% 1211 (42) 483 (62) 288 (45) 171 (48) 68 (37) 2221 (46)
[0, 10]% 793 (27) 141 (18) 153 (24) 77 (21) 52 (28) 1216 (25)
[10, 50]% 679 (23) 114 (15) 146 (23) 72 (20) 53 (29) 1064 (22)
[50, 100]% 227 (8) 36 (5) 56 (9) 39 (11) 12 (6) 370 (8)
CD8 count
Data available 2893 (100) 758 (100) 627 (100) 325 (100) 154 (100) 4757 (100)
0 TIL 479 (17) 193 (25) 295 (47) 157 (48) 40 (26) 1164 (24)
1–2 TIL 481 (17) 136 (18) 135 (22) 73 (22) 40 (26) 865 (18)
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Cohen’s κ and its weighted variant were, respectively, used to
assess inter-rater reliability for categorical and ordinal outcomes,
where −1, 0 and 1 represent complete disagreement, agreement
by chance and complete agreement, respectively. The strength of
association was described as recommended by Landis and Koch.23
RESULTS
PTEN loss is prevalent across all histotypes of ovarian cancer
Classically PTEN acts as a cytoplasmic protein but is also expressed
in the nucleus, where it may have several regulatory functions.24 In
order to evaluate the reproducibility of both cytoplasmic and
nuclear scoring, two observers compared 678 scores randomly
assigned across all TMAs evaluated in this study (~4.4% of the
original cohort). PTEN cytoplasmic scoring was reproducible
between observers (Cohen’s weighted κ= 0.59 for the ‘negative’,
‘weak’ and ‘positive’ ordinal levels; 95% confidence interval (CI)
0.53–0.64) and inter-observer differences were mostly seen when
assessing if a core had heterogeneous PTEN expression (Supple-
mentary Fig. 2, Supplementary Table S2). Scoring of PTEN nuclear
expression was less reproducible (Cohen’s weighted κ= 0.49 for
the ‘0%’, ‘<10%’, ‘10–50%’ and ‘>50%’ ordinal levels; 95% CI
0.43–0.54). As PTEN is also infrequently expressed in the nucleus,
only cytoplasmic staining was used for further analyses.
Loss of PTEN IHC cytoplasmic expression was statistically more
frequent in endometrioid and clear cell histotypes, with 35% and
32% cases having complete absence of expression, respectively
(Fig. 1, Supplementary Figure 3). In HGSOC, the proportion of PTEN
loss or downregulation (scored as absent, weak or heterogeneous
staining) was very similar to that observed in our previous smaller
cohort (75% versus 77%, respectively).15
Early clonal loss of PTEN is a common event and late sub-clonal
loss of PTEN is more common in advanced stages in HGSOC
PTEN loss appears in pre-invasive lesions in the fallopian tube and
therefore is a putative early driver in HGSOC.25 Our results show
that loss of PTEN expression was similar across all stages of HGSOC
(with the exception of moderately lower prevalence of PTEN
negativity in stage II), consistent with previous evidence that PTEN
is commonly lost early in tumour progression (Fig. 2a). Interest-
ingly, heterogeneous expression of PTEN (suggestive of sub-clonal
loss of PTEN) was more frequent in more advanced stages of the
Table 1 continued
Cancer type Total
HGSOC ENOC CCOC MOC LGSOC
3–19 TIL 1278 (44) 301 (40) 119 (19) 82 (25) 63 (41) 1843 (39)
20+ TIL 655 (23) 128 (17) 78 (12) 13 (4) 11 (7) 885 (19)
AR expression
Data available 2603 (100) 662 (100) 564 (100) 317 (100) 175 (100) 4321 (100)
Negative 1669 (64) 459 (69) 532 (94) 305 (96) 109 (62) 3074 (71)
Positive 934 (36) 203 (31) 32 (6) 12 (4) 66 (38) 1247 (29)
PR expression
Data available 1674 (100) 590 (100) 504 (100) 267 (100) 86 (100) 3121 (100)
Negative 1068 (64) 167 (28) 469 (93) 235 (88) 34 (40) 1973 (63)
1–50% positive 457 (27) 111 (19) 25 (5) 18 (7) 26 (30) 637 (20)
>50% positive 149 (9) 312 (53) 10 (2) 14 (5) 26 (30) 511 (16)
ER expression
Data available 1258 (100) 363 (100) 336 (100) 161 (100) 66 (100) 2184 (100)
Negative 289 (23) 91 (25) 283 (84) 133 (83) 9 (14) 805 (37)
1–50% positive 277 (22) 66 (18) 21 (6) 6 (4) 13 (20) 383 (18)
>50% positive 692 (55) 206 (57) 32 (10) 22 (14) 44 (67) 996 (46)
The same information in person-year units is available in Supplementary Table 1.
TIL tumour-infiltrating lymphocytes.
Fig. 1 Prevalence of different levels of PTEN expression across
histotypes of ovarian cancer. Mosaic representing the frequency of
different scoring for PTEN expression using IHC per histotype with
tiles of size proportional to their observed frequencies and colour
coded according to their (signed) contributions to the Pearson’s Chi-
square statistics. Blue and red tiles, respectively, correspond to cells
showing frequencies smaller and greater than expected under the
independence assumption. Refer to Supplementary Fig. 3 for the
barplots of the absolute and relative frequency of the PTEN scores
per histotype.
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disease (from 4% in stage I to 8% in stage IV; gCMH p value=
0.0187 for a Cochran–Armitage trend test) and subgroup analysis
shows that this association is present only in the context of absent
BRCA1/2 pathogenic mutation (see Supplementary Information).
In contrast to our previous reported results, loss of PTEN
expression was not an adverse prognostic factor and had a
modest positive effect on overall survival (hazard ratio (HR) 0.78,
95% CI 0.65–0.94; p value= 0.022 after multiplicity correction;
Fig. 2b and Supplementary Table 3). Similar results were obtained
with sensitivity analyses controlling for CD8, ER, PR and AR
independently or jointly, suggesting that the effect of PTEN is
additional to the effect of these biomarkers.
HGSOC and CCOC show distinct associations between PTEN
expression and CD8 counts
In HGSOC, CD8 counts were higher than in any other histotype of
ovarian cancer (Fig. 2c). In preclinical models of melanoma, loss of
PTEN was associated with decreased intra-tumour T cells.4 In this
study, higher levels of PTEN expression were associated with lower
CD8 counts in CCOC (gCHM test p value < 0.0001 for an ordinal/
ordinal association; Fig. 2d and Supplementary Table 4). The
average CD8 count per cytoplasmic PTEN level was also different
in HGSOC (gCHM test p value= 0.0052 for a nominal/ordinal
association, Fig. 2e and Supplementary Table 4). More strikingly,
heterogeneous expression of PTEN in HGSOC (suggestive of sub-
clonal loss of PTEN) was associated with significantly higher CD8
counts (gCHM test p value= 0.0016 for a binary/ordinal associa-
tion corresponding to Cochrane–Armitage trend test; Fig. 2e).
PTEN expression was strongly associated with AR, ER and PR
expression in HGSOC
In ENOC, PTEN loss was more prevalent in younger (<50 years)
than in older patients (gCHM test p value < 0.0001 for an ordinal/
ordinal association; Supplementary Table S3 and Fig. 3a), and
this was likely related to the previously described hormonal
regulation of PTEN expression. We also found that PTEN
expression was strongly and positively associated with expres-
sion of ER, PR and AR in HGSOC (Supplementary Table 4;
Fig. 3b–d).
DISCUSSION
The standard treatment of ovarian cancer has remained the same
for the past two decades since the introduction of taxanes to
platinum-based therapies, with very modest improvements in
survival that are most likely related to improvements in supportive
care. In order to define better therapeutic strategies, it is crucial to
accurately describe the prevalence of common drivers and how
a b
c d e
Fig. 2 Association between levels of PTEN expression, stage, survival, and CD8 expression across ovarian cancer histotypes. aMosaic plot
corresponding to the association analysis between PTEN expression and stage of disease. b Kaplan–Meier survival curves for PTEN-negative,
PTEN-positive, weak or heterogeneous staining for HGSOC from study cohort (multivariate hazard ratio 0.78, 95% CI 0.64–0.93, N= 1842, p=
0.0205 after multiplicity correction, when comparing PTEN negative vs PTEN positive). CI confidence interval. c Mosaic plot for the association
between levels of CD8 expression and histotypes of ovarian cancer. Mosaic plots (d, e) summarise the association between PTEN expression
and CD8 counts in CCOC and HGSOC, respectively. TIL tumour-infiltrating lymphocytes.
Clinical and pathological associations of PTEN expression in ovarian. . .
FC Martins et al.
797
they associate with clinical features and biomarkers of actionable
pathways.2
Our large study of 5400 patients with ovarian cancer showed
that complete loss of PTEN is highly prevalent across different
histotypes of ovarian cancer ranging from 11% in LGSOC and 35%
in CCOC, suggesting that it may be a driver of the disease. A small
number of molecular alterations are generally sufficient to drive
tumour initiation and progression.26 As HGSOC and its pre-
cancerous lesions in the fallopian tubes have highly complex
genomes27–29 and there is marked heterogeneity between
patients, the identification of important drivers is challenging.
Our results show a similar frequency of complete PTEN loss across
all stages of HGSOC, which is consistent with loss of PTEN as a
common early step in the progression of HGSOC. In BRCA1-
associated breast cancer, which has molecular similarities with
HGSOC (e.g., genomic instability, chromosomal complexity,
frequent TP53, BRCA1 and BRCA2 mutation), PTEN loss was also
the most frequent initiating event.18 Interestingly, we found here
that the frequency of HGSOC cases with heterogeneous expres-
sion of PTEN (suggestive of a later sub-clonal loss of PTEN) is
higher in more advanced disease in patients without any
confirmed pathogenic BRCA1/2 mutation. As stage is a surrogate
for increased tumour mass, this suggests that PTEN loss confers a
proliferative advantage to tumour cells and is positively selected
over HGSOC cell expansion. PTEN loss is also one of the most
frequent hits for increased cell viability in CRISPR screens.30
Considering the role of the PI3K pathway in the regulation of
genomic stability, it is difficult to ascertain if loss of PTEN by
chromosomal deletion is a result of baseline genomic instability or
if it influences the latter.31 Therefore, despite the clinical and
pathological associations we presented, it remains inconclusive if
loss of PTEN is a driver of the disease initiation or progression.
Previous evidence of PTEN loss in early pre-cancer lesions in
the fallopian tubes,25 its role in the mouse models of HGSOC12–14
and high focal prevalence of PTEN loss compared to other
neighbouring genes (Gistic p value for the likelihood of PTEN loss
being a driver: 7.3e−17)11,32 in HGSOC are supportive of the role
of PTEN loss in driving progression in HGSOC. Whole-genome
characterisation of chemoresistant ovarian tumours also sug-
gested that gene breakage of PTEN and other tumour-suppressor
genes also contributes to chemoresistance.33
The majority of ENOC arise from malignant transformation of
endometriosis, suggesting that pathways involved in the trans-
formation of this ectopic endometrium into ENOC may overlap
with the processes involved in the progression from normal
endometrium to endometrial cancer.34 In this context, PTEN loss is
commonly lost in the normal endometrium.35 In our study, the
frequency of PTEN loss in ENOC was significantly higher in
younger premenopausal patients whose higher levels of oestra-
diol and progesterone induce higher expression and phosphor-
ylation of PTEN in the endometrium.5 This suggests that deletion
of PTEN is therefore more likely to be positively selected and to
a b
c d
Fig. 3 Association between levels of PTEN expression, age, and expression of hormonal receptors across ovarian cancer histotypes.
a Mosaic plot summarising the association between PTEN expression and age groups in ENOC. b–d are mosaic plots summarising the
association between levels of expression of PTEN and hormonal receptors (oestrogen receptor, progesterone receptor, and androgen
receptor, respectively) in HGSOC.
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provide a proliferative advantage in the context of a surrounding
endometrium with upregulated PTEN than within the endome-
trium of older postmenopausal patient where lower hormonal
levels already condition lower levels of PTEN expression. In this
context, we found a strong association between expression of
hormonal receptors (AR, ER and PR) and PTEN expression in
HGSOC. Activity of the PTEN/PI3K pathway has also been
associated with AR expression in prostate cancer,20,36 and mouse
models suggest that a functional AR may increase PTEN
inactivation-induced uterine cancer.37 These data suggest that
PTEN inactivation is positively selected by functional androgen
activity in these tumour types.
In a previous study, we found in two smaller cohorts that cases
with any type of loss of PTEN expression was associated with
shorter overall survival. Although this association was significant,
the confidence intervals were relatively wide (N= 439; HR 1.5,
95% CI 1.1–2.0).15 In this much larger cohort, the frequency of
loss was similar, but there was an opposite prognostic signal,
reinforcing the need to use large cohorts for validation
of putative prognostic biomarkers. The association between
PTEN negative expression in HGSOC and longer overall survival
(HR 0.78 95% CI 0.64–0.93) is counterintuitive considering that
activation of the PI3K pathway is generally associated with
proliferation and more aggressive tumours. We speculate that
further genetic interactions may be important in determining
survival. For instance, if PTEN loss appears stochastically in the
context of existing homologous recombination deficiency,
accelerated proliferation on a background chromosomal instabil-
ity may increase genomic crisis and cell death. In addition, loss
of PTEN may have treatment interactions particularly with
platinum-based chemotherapy as higher proliferation and
genomic instability predict better response.38
A multi-omics approach also demonstrated that immune-
infiltrate of cytotoxic T cells can be recruited to the tumour by
cytokines derived from the activation of the DNA damage
response protein ATM in tumours that are genomically unstable
and therefore enriched for chromosomal copy number alterations
(CNAs),39 supporting previous associations between BRCA-like
HGSOC (characterised by homologous recombination deficiency)
and immune infiltrates.11,40 In previous studies, CD8 counts were
indeed highest in HGSOC (the ovarian cancer histotype with
higher prevalence of CNAs) as compared to other histotypes, and
higher CD8 counts were associated with longer survival in HGSOC
and ENOC.16 Despite the associations we found between
expression of PTEN and CD8 counts in HGSOC, they seem to
have opposite effects on survival. More specifically, PTEN loss and
higher CD8 counts seem to have positive effects on prognosis,
which may be explained by their association with CNA-enriched,
genomically unstable tumours. This is further supported by the
fact that the highest CD8 counts were found in tumours with
heterogeneous expression of PTEN (and likely late sub-clonal loss
of PTEN).
Preclinical murine models of melanoma suggest that PTEN loss
promotes resistance to T cell-mediated immunotherapy by
decreasing T cell trafficking into the tumours.4 Moreover, trials
of PI3Kbeta inhibitor in this model improved the efficacy of both
anti-PD-1 and anti-CTLA-4 antibodies. Recent in silico and IHC
analysis of human prostate tumours showed that PTEN loss in
primary prostate tumours was also associated with lower CD8+
TIL counts and an immunosuppressive tumour environment
mediated by infiltrating FoxP3+ T cells.41 However, in the same
study, PTEN-deficient metastasis to the lymph nodes showed
increased counts of CD8+ T cells. Interestingly, these opposite
associations are also demonstrated in our study, since PTEN loss
was associated with low counts of CD8+ T cells in HGSOC cases
and high counts in CCOC cases, supporting the hypothesis that
not only PI3K activation may influence recruitment of cytotoxic
T cells but also that these processes may be distinctly regulated in
different subtypes of ovarian cancer.
PTEN loss is known to preferentially activate the PI3Kbeta
subunit and we show that PTEN loss is a common event in
all types of ovarian cancer and can appear in the context
of chromosomal instability in HGSOC. These results suggest
that combinations of small molecule inhibitors targeting the
PI3K/AKT/mammalian target of rapamycin pathway (including
inhibitors of the beta subunit), poly ADP-ribose polymerase or
apoptotic pathways may have effective results in cases of HGSOC
in the clinical setting. Preclinical studies using combinations of
those agents have already shown promising results.42–44 More-
over, the associations we found between expression of PTEN and
hormonal receptors suggest that molecular stratification based on
expression of PTEN and hormonal receptors may be informative
for tumours that are more likely to respond to hormonal therapies
(high expression of PTEN and hormonal receptors) and those that
could be preferentially treated with PI3Kbeta inhibitors (low
expression of PTEN and hormonal receptors). Finally, future
validation in primary cells from patients to assess if and how
PTEN regulates recruitment of cytotoxic T cells may inform how
the drug combinations above can be used to improve immu-
notherapy results. In summary, this work will inform future trials in
ovarian cancer using combinations of immunotherapy and other
targeted therapies and suggests that profiling for PTEN expression
should also be done in the context of those trials.
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